Viking Therapeutics SG&A Expenses 2014-2024 | VKTX

Viking Therapeutics sg&a expenses for the twelve months ending September 30, 2024 were $0.043B, a 32.36% increase year-over-year.

  • Viking Therapeutics annual sg&a expenses for 2023 were $0.037B, a 129.64% increase from 2022.
  • Viking Therapeutics annual sg&a expenses for 2022 were $0.016B, a 50.65% increase from 2021.
  • Viking Therapeutics annual sg&a expenses for 2021 were $0.011B, a 0.28% decline from 2020.

Viking Therapeutics SG&A Expenses 2014-2024 | VKTX

  • Viking Therapeutics annual sg&a expenses for 2023 were $0.037B, a 129.64% increase from 2022.
  • Viking Therapeutics annual sg&a expenses for 2022 were $0.016B, a 50.65% increase from 2021.
  • Viking Therapeutics annual sg&a expenses for 2021 were $0.011B, a 0.28% decline from 2020.